GuyanaTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.16 (0.14–0.17) 21 (18–23)
Mortality (HIV+TB only) 0.042 (0.033–0.052) 5.5 (4.3–6.8)
Prevalence  (includes HIV+TB) 0.94 (0.47–1.6) 123 (61–205)
Incidence  (includes HIV+TB) 0.79 (0.7–0.89) 103 (91–116)
Incidence (HIV+TB only) 0.17 (0.14–0.2) 22 (19–26)
         
Case detection, all forms (%) 69 (62–78)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.2–3.8) 11 (6.1–17)
MDR-TB cases among notified pulmonary
TB cases
11 (5–17) 17 (9–25)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 284   19
Pulmonary, clinically diagnosed 153   31
Extrapulmonary 58   0
       
Total new and relapse 545    
Previously treated, excluding relapses 103    
Total cases notified 648    
Among 545 new and relapse cases:
11 (2%) cases aged under 15 years; male:female ratio: 2.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 6 (2%) 41 (27%) 41
Laboratory-confirmed RR-/MDR-TB cases     4
Patients started on MDR-TB treatment ***     4
TB/HIV 2014 Number (%)
TB patients with known HIV status 587 (91)
HIV-positive TB patients 148 (25)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 135 (91)
HIV-positive TB patients on antiretroviral therapy (ART) 103 (70)
HIV-positive people screened for TB 4 864  
HIV-positive people provided with IPT 44  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (67) 680
Previously treated cases, excluding relapse, registered in 2013 (47) 106
HIV-positive TB cases, all types, registered in 2013 (63) 139
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.6
Culture (per 5 million population) 6.5
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 1.3
% Funded domestically 25%
% Funded internationally 58%
% Unfunded 17%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-29 Data: www.who.int/tb/data